Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer.

Sabine HeubleinMarkus EggerJunyan ZhuLuisa BergerDoris MayrChristian SchindlbeckChristina KuhnSimone S HofmannFlorian SchuetzUdo JeschkeNina Ditsch

Published in: Breast cancer research and treatment (2019)

The data presented here further support a role of TF in BC tumor biology. Whether anti-TF directed treatment approaches may gain clinical relevance in those cases determined as triple negative or TA-MUC1 positive remains to be determined.

Keyphrases

electronic health record
big data
machine learning
young adults
replacement therapy